Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
2013-001879-20Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Oct 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin and carfilzomib in peripheral T-cell lymphoma (PTCL), sponsored by University of Birmingham. Primary endpoints: Maximum tolerated dose of romidepsin + carfilzomib and Dose-limiting toxicities (DLTs). Status: unknown.
02
Drugs
romidepsincarfilzomib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2013-001879-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001879-20.